- Home
- PHGE vs ICCM Comparison
PHGE vs ICCM Comparison
Compare PHGE & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- ICCM
- Stock Information
- Founded
- PHGE 2015
- ICCM 2006
- Country
- PHGE Israel
- ICCM Israel
- Employees
- PHGE N/A
- ICCM N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- PHGE Health Care
- ICCM
- Exchange
- PHGE Nasdaq
- ICCM Nasdaq
- Market Cap
- PHGE 26.5M
- ICCM 29.3M
- IPO Year
- PHGE N/A
- ICCM N/A
- Fundamental
- Price
- PHGE $0.75
- ICCM $0.59
- Analyst Decision
- PHGE Strong Buy
- ICCM Strong Buy
- Analyst Count
- PHGE 2
- ICCM 2
- Target Price
- PHGE $22.50
- ICCM $2.70
- AVG Volume (30 Days)
- PHGE 151.9K
- ICCM 1.1M
- Earning Date
- PHGE 11-14-2024
- ICCM 11-18-2024
- Dividend Yield
- PHGE N/A
- ICCM N/A
- EPS Growth
- PHGE N/A
- ICCM N/A
- EPS
- PHGE N/A
- ICCM N/A
- Revenue
- PHGE N/A
- ICCM $3,336,000.00
- Revenue This Year
- PHGE N/A
- ICCM $18.61
- Revenue Next Year
- PHGE N/A
- ICCM $54.91
- P/E Ratio
- PHGE N/A
- ICCM N/A
- Revenue Growth
- PHGE N/A
- ICCM 3.60
- 52 Week Low
- PHGE $0.62
- ICCM $0.48
- 52 Week High
- PHGE $8.55
- ICCM $1.57
- Technical
- Relative Strength Index (RSI)
- PHGE 36.37
- ICCM 38.10
- Support Level
- PHGE $0.67
- ICCM $0.54
- Resistance Level
- PHGE $0.81
- ICCM $0.85
- Average True Range (ATR)
- PHGE 0.09
- ICCM 0.10
- MACD
- PHGE 0.00
- ICCM -0.02
- Stochastic Oscillator
- PHGE 44.00
- ICCM 4.35
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.